Protected by international patents, Stablor® composition combines specific fractions of milk proteins with selected amino acids. Stablor®’s specificity lies in the fact that it targets obesity-related metabolic and nutritional disorders of obese patients with metabolic syndrome (increased waist size associated with 2 other metabolic disease risk factors).
Mode of action
POC in Human
This trial demonstrated Stablor®’s clinical efficacy in significantly reducing visceral fat loss, as well as other metabolic markers.
In addition, OBEMINALE 1 allowed to point out Stablor® as a modulator of gut microbiome through the promotion if a specific family of bacteria known for its anti-obesity potential. This has been a major breakthrough and a driving force behind LNC Therapeutics’s strategy.
Targeting EFSA approval
The OBEMINALE 2 trial was developed in accordance with pharmaceutical industry standards (multi-center, randomized, double-blind, placebo-controlled) and targets 240 obese patients with metabolic syndrome.
The trial launch and treatment of the first patient were announced in October 2018. The final results are expected to be available by the end of 2019.
EFSA 13(5) health claims are based on newly established scientific evidence and include an application to protect data relating to the applicant’s exclusive property.
Our program is built on first-class scientific publications that have identified Christensenella to be a cornerstone of healthy human intestinal microbiota. We have also secured a strong IP position in this field to successfully pursue our vision and our development strategy
LNC Therapeutics is currently considering obesity and associated metabolic disorders as the lead indication because this is where a causal relationship between C. minuta and health have been established.
Why Christensenella ?
LNC Therapeutics, is the first company to harness the therapeutic potential of christensenella
6 highlights on research progress
In 2014, it was identified as the most heritable bacterial taxon in humans and was found to be significantly reduced in obese European individuals (Goodrich et al. 2014).
These observations were rapidly confirmed in an independent study in 2015 (Fu et al. 2015). In addition, high levels of C. minuta in the 2015 cohort were associated with reduced circulating levels of triglycerides and higher HDL cholesterol (also known as “good” cholesterol).
Disappearance of C. minuta bacteria has since been associated with other conditions such as inflammatory bowel disease (Pascal et al. 2017, Kummen et al. 2017, Zakrzewski et al. 2018).
Today, LNC Therapeutics is a pioneer in the use of christensenella’s therapeutic potential. We envision the use of the living bacteria formulated in a pill or the metabolites it secretes for the development of these new therapies.